ImageVerifierCode 换一换
格式:PPT , 页数:46 ,大小:3.87MB ,
资源ID:2162457      下载积分:20 金币
快捷下载
登录下载
邮箱/手机:
温馨提示:
快捷下载时,用户名和密码都是您填写的邮箱或者手机号,方便查询和重复下载(系统自动生成)。 如填写123,账号就是123,密码也是123。
特别说明:
请自助下载,系统不会自动发送文件的哦; 如果您已付费,想二次下载,请登录后访问:我的下载记录
支付方式: 支付宝    微信支付   
验证码:   换一换

加入VIP,免费下载
 

温馨提示:由于个人手机设置不同,如果发现不能下载,请复制以下地址【https://www.docduoduo.com/d-2162457.html】到电脑端继续下载(重复下载不扣费)。

已注册用户请登录:
账号:
密码:
验证码:   换一换
  忘记密码?
三方登录: 微信登录   QQ登录   微博登录 

下载须知

1: 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。
2: 试题试卷类文档,如果标题没有明确说明有答案则都视为没有答案,请知晓。
3: 文件的所有权益归上传用户所有。
4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
5. 本站仅提供交流平台,并不能对任何下载内容负责。
6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。

版权提示 | 免责声明

本文(支架内血栓李建平.ppt)为本站会员(微传9988)主动上传,道客多多仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对上载内容本身不做任何修改或编辑。 若此文所含内容侵犯了您的版权或隐私,请立即通知道客多多(发送邮件至docduoduo@163.com或直接QQ联系客服),我们立即给予删除!

支架内血栓李建平.ppt

1、支架内血栓 In-Stent Thrombosis,北京大学第一医院 李建平,Definite/Confirmed (肯定的) Acute coronary syndrome AND Angiographic confirmation of thrombus or occlusion OR Pathologic confirmation of acute thrombosis Probable (可能的) Unexplained death within 30 days Target vessel MI without angiographic confirmation of thrombos

2、is or other identified culprit lesion Possible (不能排除的) Unexplained death after 30 days,ARC 支架内血栓定义,支架内血栓的预后,Similar mortality observed for SES and BMS thrombosis,Pooled Data from RAVEL, SIRIUS, C-SIRIUS, E-SIRIUS,支架内血栓发生时间,ST = stent thrombosis; SAT = subacute stent thrombosis; LST = late stent thro

3、mbosis; VLST = very late stent thrombosis. Adapted from Bhatt. J Invasive Cardiol. 2003;15(suppl B):3B.,Stent Thrombosis (%),支架内血栓与抗凝、抗血小板治疗,ASA und Ticlopidine,ASA und Anticoagulation,ASA und Clopidogrel,ASA = Acetylsalicylic acid DES: Drug-eluting stent,Bare Metal Stent,Prasugrel?,DES肯定的ST发生率: Ber

4、n - Rotterdam Cohort Study Daemen, Wenaweser et al. Lancet 2007;369:667-78,N=8146,0,1,2,3,4,Time since PCI in years,0,1,2,3,4,5,Cumulative incidence, %,Incidence density 1.0 / 100 pt years,3.3%,3.5,0.53% (95% CI=0.44-0.64)/ year,192 definite ST cases,DES肯定的ST发生率: Bern-Rotterdam Cohort Study 4 Years

5、Wenaweser P et al. J Am Coll Cardiol 2008, 52, 1134-,0.52% (95% CI=0.42-0.62)/ year between 30 days and 5 years,DES肯定的支架内血栓发生率: Bern-Cohort Study 5 Years Wenaweser P et al. ESC 2008,DES vs BMS A cohort of 9,175 patients treated with either BMS or DES (SES or PES), all patients with angiographically

6、documented ST were identified as cases,Early Stent Thrombosis,RR=0.76 95% CI =0.30-1.80 P=0.55,RR=0.80 95% CI =0.32-2.03 P=0.79,Meta-analysis SES vs BMS Bavry A et al. Am J Card 2005,Meta-analysis PES vs BMS Stone G et al. NEJM 2007,%,%,Very Late ST 1 Year (Per Protocol),P=0.75,P=0.02,%,P=0.30,P=0.0

7、3,%,Stone G et al. NEJM 2007;356:998-1008,Kastrati A et al. NEJM 2007;356:1030-9,Sirolimus-Eluting Stent,Paclitaxel-Eluting Stent,SIRTAX Definite ST 4 Years Windecker S et al ESC 2008,2.0%,1.8%,2.8%,2.4%,3.7%,3.4%,Cumulative Incidence of Definite ST in LEADERS (BES vs. SES) Windecker et al. Lancet,

8、2008, 372, 1163-,Overall Incidence of ST with DES,ENDEAVOR,XIENCE,BIOMATRIX,High Risk of ST in All-Comer Patient Population and STEMI Patients,%,支架内血栓的病因,STENT THROMBOSIS,Patient Genetic Polymorphism Reduced LV-EF Acute Coronary Syndrome Hematology Disorder,Drugs Resistance Drug-drug Interaction Dur

9、ation of Antiplatelet Treatement,Vessel Reaction Vessel Remodeling Hypersensitivity Reaction Delayed Healing,早期支架内血栓的预测因素: 残留夹层/撕裂,Bare Metal Stents MACE 30 days Schhlen H et al. Circulation 1998,N=2,894,Drug-Eluting Stents MACE 30 days Biondi-Zoccai G et al. EHJ 2006,N=2,418,%,P=0.01,P=0.01,Residua

10、l Dissection: Independent Predictor of MACE (OR=2.9),早期支架内血栓IVUS预测因素 With the Use of Sirolimus-Eluting Stents Fujii K et al. J Am Coll Cardiol 2005;45:995-8,Minimal Stent CSA,P0.001,mm2,Stent Expansion,Residual Stenosis,%,P0.001,Stent Underexpansion and Residual Reference Segment Stenosis: Independe

11、nt Predictors of Early Stent Thrombosis!,P0.001,支架内血栓预测因素 药物反应异常 Wenaweser P et al. JACC 2005; 45(11):1748-52,服药后血小板活性与DES ST的关系 Buonamici P et al JACC 2007,p0.001,p0.001,p0.001,p=ns,Iakovou et al JAMA 2005,Park et al Am J Card 2006,Airoldi et al Circulation 2007,Kuchulakanti et al Circulation 2006,

12、OR=89.8 (29.9-270),HR=19.2 (5.6-65.5),HR=13.7 (4.0-46.7),OR=4.8 (2.0-11.1),Odds/Hazard Ratio,过早停用抗血小板药物是支架内血栓的重要预测因素,支架内血栓发生时的抗血小板治疗 Bern-Rotterdam Cohort Study 5 Years Wenaweser P et al. ESC 2008,Triton TIMI 38 Prasugrel vs. Clopidogrel in ACS Patients With Stents Wiviott SD et al. Lancet 2008;371:

13、1353-63,Overall Stent Thrombosis,Early Stent Thrombosis,Late Stent Thrombosis,Park et al Am J Card 2006,Airoldi et al Circulation 2007,Iakovou et al JAMA 2005,Machecourt et al JACC 2007,OR=1.03 (1.00-1.05),OR=1.01 (1.00-1.03),OR=2.75 (1.55-4.88),Odds Ratio,支架内血栓的预测因素-支架长度,OR=1.02 (1.00-1.04),OR=1.08

14、 (1.06-1.1),De la Torre et al JACC 2008,Roy et al J Interv Card 2007,Kuchulakanti et al Circulation 2006,OR=4.4 (2.0-10.0),Odds Ratio,支架内血栓的预测因素-分叉病变,OR=2.4 (1.1-5.6),Iakovou et al JAMA 2005,OR=6.4 (2.9-14.1),Ong et al JACC 2005*,OR=12.9 (4.7-35.8),*in setting of AMI,Joner et al JACC 2006,Park et al

15、 Am J Card 2006,Daemen et al Lancet 2007,Urban et al Circulation 2006,OR=12.4 (1.7-89.7),OR=2.3 (1.3-4.0),OR=1.8 (1.1-2.7),Odds/Hazard Ratio,支架内血栓的预测因素-ACS,De la Torre et al JACC 2008,HR=2.6 (1.3-4.9),Impact of Thrombus Burden on Risk of ST With DES in Patients With STEMI Sianos G et al. J Am Coll C

16、ardiol 2007;50:573-83,Independent Predictors of ST,Kuchulakanti Circ 2006,Urban Circ 2006,Iakovou JAMA 2005,Daemen Lancet 2007,Machecourt JACC 2007,OR=2.0 (0.8-4.9),OR=2.8 (1.7-4.3),HR=3.7 (1.7-7.9),HR=2.0 (1.1-3.8),OR=2.7 (1.4-5.2),Odds/Hazard Ratio,支架内血栓的预测因素-糖尿病,Iijima Am J Card 2007,HR=2.2 (1.1-

17、4.3),HR=1.75 (1.0-3.0),De la Torre JACC 2008,晚期支架内血栓的可能原因,Chronic inflammatory reaction to the polymer or drug Hypersensitivity to the polymer or drug Failure of stents to completely reendothelialize completely Late incomplete stent apposition Disease progression,多聚物高敏,获得性晚期支架贴壁不良,Baseline 8 mo foll

18、ow-up,SIRIUS Trial: 7/80 (8.7%) patients, no 12-month MACEAko J. et al. JACC 2005;46:1002-5,Cook et al. Circulation 2007,Kotani et al. JACC 2006,Joner et al. JACC 2006,Togni et al. JACC 2005,Abnormal Vasomotion,Delayed Healing,Delayed Endothelialization,Vessel Remodeling,DES后病生理机制,Endothelialization

19、,小结,DES支架内血栓发生率: Early: 0.5% - 1.6% Late/Very late: 0.3% - 0.6%预测因素 Residual dissection, stent underexpansion Diabetes, ACS, bifurcation stenting, stent length, thrombus burden, late aquired stent malapposition, ineffective platelet inhibition,支架内血栓的预防,高危病人的辨认 避免过度支架 长支架, 分叉支架, 支架重叠 支架植入的理想结果 无残留撕裂/

20、夹层 支架膨胀良好 增加抗血小板治疗的有效性 高危病人评估抗血小板药物的反应性 再狭窄低危病人中使用BMS,专家共识,FDA DES Panel Meeting,There is an increase in “very late” (1 yr) stent thrombosis associated with current DES 2-4 per 1000 pts per year (? continous hazard, ? patient and lesion predictors) Data from multiple sources indicate that DES are as

21、sociated with delayed healing responses and increased inflammation The causes of late DES thrombosis are multi- factorial; device, procedural, and patient factors (often multiple = perfect storm),专家共识,FDA DES Panel Meeting,There may be a link between post-DES reduced neo-intimal hyperplasia (late lo

22、ss) and delayed late healing responses which contributes to late stent thrombosis DES stent thrombosis is highly definition dependent; need for revised standardized definitions and adjudication methods (ARC) to facilitate inter-study comparisons,专家共识,“Off-label DES use increased incidence of late DE

23、S thrombosis and death/MI cw “on-label”, but inadequate controls; results inconsistent! Few RCTs (underpowered); FDA sanctioned registries = insufficient sample size and FU, represents major data gap and source of concern Large population studies (SCAAR) fraught with methodologic flaws (e.g. risk ad

24、justment issues),专家共识,Duration of dual anti-platelet therapy should extend beyond the present product labels One year is reasonable compromise (esp. for “off-label” DES use) Must balance against the increased risk of bleeding with dual anti-platelet therapy Additional studies immediately required to

25、 better clarify optimal anti-platelet therapy,专家共识,Assess patient and lesion characteristics to establish restenosis risk profile Determine relative value of DES vs. BMS in every patient (no more “unrestricted” use) Consider both on-label and off-label situations (ironically, off-label use scenarios

26、 may be more compelling) Increased restenosis risk = favor DES Increased safety concerns = favor No DES,专家共识,Assess patient factors which may preclude long-term (at least one year) dual AP therapy Planned or possible intercurrent surgery Bleeding Hx or tendencies Other concomitant medications (e.g.

27、coumadin) Socio-economic factors which may affect Plavix compliance,专家共识,Consider alternatives to DES, if risk-benefit assessments prove unfavorable CABG unprotected LM disease, complex MVD (esp. diabetics), recurrent ISR (esp. VBT) BMS Plavix dependence concerns, large (4mm diameter) vessels, ? AMI

28、 pts, ? low restenosis risk lesions Balloon PCI sidebranch in bifurcations (provisional stent only), small vessels in distal locations,专家共识,Optimize DES implantation techniques Adequate lesion preparation (pre-dilatation) High pressure implantation methodologies (like previous BMS strategies) Avoid

29、undersizing and inflow/outflow obstruction (mod stenoses or dissections) Implant stent edges into normal references segments Consider IVUS guidance (esp. LAD),专家共识,Careful explanations and open communication with patients and families Careful pre-treatment history Discussion with EVERY pt re: risks and benefits of DES vs. alternative therapies Ongoing (post-Rx) communication and careful FU re: dual AP compliance (instructions = NO Plavix discontinuation without MD approval)!,DES 风险 & 获益,治疗1000个病人可以预防100个再狭窄 同时可以预防10个再狭窄相关的心肌梗死 可能会因为晚期支架内血栓增加5个心肌梗死 获益风险,

本站链接:文库   一言   我酷   合作


客服QQ:2549714901微博号:道客多多官方知乎号:道客多多

经营许可证编号: 粤ICP备2021046453号世界地图

道客多多©版权所有2020-2025营业执照举报